Advertisement
Screener

TENAX THERAPEUTICS, INC. (TENX) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

2.0 / 5 stars · 17/43 Roast Me

TENAX THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

TENAX THERAPEUTICS, INC. (TENX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $8.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.

Financial Statements › Notes › Components of Deferred Tax Assets

us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-10

  • TENAX THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $8.70M.
Period endValuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month
2025-12-31$8.70M
10-K · filed 2026-03-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
Cingulate Inc. (CING)United States$0.073B-2.64
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
XBiotech Inc. (XBIT)United States$0.066B-1.56
OS Therapies Inc (OSTX)United States$0.076B-2.17